Fig. 3
From: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
R848 improves cachexia manifestations in murine PDAC models. Mice were orthotopically implanted with one of three distinct syngeneic KPC-derived cell lines: KxPxCx, FC1199, and FC1242. Vertical dotted lines denote the onset of cachexia as defined by consistent hypophagia exceeding 10% below control food intake. KxPxCx studies were performed independently, whereas FC1242 and FC1199 studies were performed concurrently with a shared control group. a Food intake relative to sham-operated vehicle-treated mice (Sham-VEH) for sham-operated R848-treated mice (Sham-R848), KxPxCx-engrafted mice receiving vehicle (KxPxCx-VEH), and KxPxCx-engrafted mice receiving R848 (KxPxCx-R848). b, c Food intake relative to sham-operated vehicle-treated mice implanted for FC1242 (b) and FC1199 (c) treated with vehicle (VEH) or R848. d–f Body weight relative to baseline for KxPxCx (d), FC1242 (e), and FC1199 (f) throughout treatment with R848 or vehicle. g Average locomotor activity during day/sleep and night/wake cycles for KxPxCx-implanted animals treated with R848 or vehicle, binned into 6 h intervals. h Average body temperature during day/sleep and night/wake cycles for KxPxCx-implanted animals treated with R848 or vehicle, binned into 6 h intervals. Data for all panels are displayed as mean ± SEM, unless fewer than three subjects were remaining in a group, in which case individual data points are plotted. Statistics were performed as two-way ANOVA during the cachexia stage to test for main effects of tumor and treatment, and the interaction thereof, with multiple comparisons to test for main column effects. Comparisons are two-way ANOVA analyzing group by time, with multiple comparison analysis of the main column effect during cachexia stage. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
